Fibrates Prevent Paclitaxel- and Carboplatin-Induced Vascular Endothelial Dysfunction
the Cancer Therapy Advisor take:
Paclitaxel and carboplatin (TCchem) are chemotherapy agents associated with vascular toxicities caused by unclear mechanisms. Cisplatin, a platinum-containing anti-cancer agent, is known to inhibit PPARα and damage the microvascular vessels in the kidneys.
Investigators conducted a pilot study to determine whether the systemic deficiency of PPARα, caused by TCchem, is the underlying mechanism for the vascular endothelial dysfunction.
In the study, there were 45 patients with gynecological cancer who were treated with TCchem and were grouped according to their triglyceride (TG) levels. Of the 30 patients exhibiting hypertriglyceridemia during TCchem, 11 patients were given bezafibrate; 15 patients exhibited stable TG levels. Endothelial dysfunction was evaluated by measuring the flow-mediated dilation (FMD) values and serum pentraxin-3 levels before and after the administration of TCchem. Human umbilical vein endothelial cells (HUVECs) were used to assess the biological mechanisms induced by TCchem via in vitro examinations.
The results showed that TCchem contributes to endothelial dysfunction by TG-dependent and TG-independent mechanisms. The administration of TCchem caused hypertriglyceridemia in 66% of patients, and in vitro examinations showed that TCchem reduced nitric oxide production and PPARα activity in HUVECs.
However, patients treated with TCchem followed by bezafibrate showed reduced TG levels, improved FMD%, and decreased serum pentraxin-3 levels. Overall, the findings indicate that bezafibrate, a PPARα agonist fibrate, can prevent endothelial dysfunction caused by TCchem.
Paclitaxel and carboplatin (TCchem) are chemotherapy agents associated with vascular toxicities caused by unclear mechanisms.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
- FDA Approves Fulvestrant/Abemaciclib Combination for Breast Cancer
- Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?
- NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Adjuvant Trastuzumab for HER2-positive Breast Cancer: 1-year Is Optimal Therapy Duration
- Metformin May Not Improve pCR Rate in HER2-positive Breast Cancer
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma
- FDA Expands Sunitinib Indication To Include Adjuvant Therapy for Renal Cell Carcinoma